Mediwound - MDWD STOCK NEWS

MediWound (Nasdaq: MDWD) will release its first quarter 2024 financial results on May 29, 2024. The report will cover the period ending March 31, 2024.

A conference call and live webcast are scheduled for the same day at 8:30 am Eastern Time. The call will discuss financial results, provide corporate updates, and include a Q&A session. Dial-in numbers for various regions and a webcast link are provided. An archived version of the webcast will be available on the MediWound website after the event.

MediWound will present new data from EscharEx Phase II studies at three major wound care conferences. The data show EscharEx's superiority over SANTYL, a leading enzymatic debridement agent, and a strong correlation between wound bed preparation and healing. The findings support the upcoming Phase III study's design and endpoints, indicating potential significant advancements in wound care.

MediWound (MDWD) reported $19 million revenue in 2023 with a projected $24 million revenue in 2024. NexoBrid® was commercially launched in the U.S., Japan, and India. EscharEx® is set to begin Phase III in the second half of 2024. The company has a $42 million cash runway through profitability.

MediWound Ltd. (MDWD) will release its financial results for Q4 and full year 2023 on March 21, 2024. A conference call and webcast will follow to discuss the results and provide updates.

MediWound Ltd. announces EscharEx superiority over SANTYL in wound debridement and wound closure for chronic venous leg ulcers. Phase II study shows EscharEx outperforming SANTYL in complete debridement, granulation tissue promotion, and wound closure time. Promising results position EscharEx as a potential market leader in enzymatic agents for chronic wound treatment.

MediWound Ltd. (Nasdaq: MDWD) will participate in the Oppenheimer 34th Annual Life Sciences Conference on February 13-14, 2024, and the TD Cowen 44th Annual Health Care Conference on March 4-6, 2024. The management team will host one-on-one meetings during both conferences, and interested investors can schedule meetings through their Oppenheimer and/or TD Cowen representative. Links to access the fireside chat and company presentation will be posted on MediWound’s website. The company is focused on next-generation enzymatic therapeutics for tissue repair.

MediWound Ltd. (MDWD) announced that the U.S. FDA has accepted a supplement to the NexoBrid biologics license application for the removal of eschar in pediatric patients with deep partial- and/or full-thickness thermal burns. NexoBrid is already approved for use for burn patients across all age groups in Europe and Japan. The sBLA seeks to expand the label for NexoBrid to include both adult and pediatric burn patients of all ages, based on the results of a global Phase 3 clinical trial.

MediWound Ltd. (Nasdaq: MDWD) awarded an additional $6.7 million to advance NexoBrid as a non-surgical field care solution, increasing the R&D project budget to $14.4 million. The U.S. Department of Defense, through the Medical Technology Enterprise Consortium, granted the funding to develop NexoBrid as a non-surgical solution for field-care burn treatment for the U.S. Army. The project aims to advance the development and production of a new, temperature-stable formulation of NexoBrid, positioning it as the first-line non-surgical solution for treating severe burn injuries in pre-hospital settings. Vericel Corporation holds an exclusive license encompassing the commercial and development rights to NexoBrid in North America. The additional funding will enhance CMC activities, expedite preclinical development, and facilitate the establishment of a GMP compliant aseptic production line for the temperature-stable formulation of NexoBrid. The MTEC Research Project Award was granted by the DoD’s U.S. Army Medical Research and Development Command and funded by the Defense Health Agency through MTEC, a biomedical technology consortium working to advance innovative medical solutions to keep military personnel healthy and fully operational.

MediWound Ltd. (Nasdaq: MDWD) announces positive results from a Phase II study of EscharEx, a novel bromelain-based enzymatic debridement agent, in patients with venous leg ulcers and diabetic foot ulcers. The study shows that EscharEx effectively debrides wounds, reduces biofilm and bacterial load, achieving complete debridement in 70% of patients within a median time of 5.5 days. The treatment also led to an average reduction of 35% in wound size and was well tolerated. The company plans to initiate a Phase III pivotal study in the second half of 2024.